Dan O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

Gilead to lay off 110+ em­ploy­ees at for­mer Im­munomedics HQ in an­oth­er ding for its $21B deal

Af­ter a Phase III read­out for the cen­ter­piece of its $21 bil­lion Im­munomedics ac­qui­si­tion un­der­whelmed Wall Street, Gilead is bring­ing out the axe.

The Cal­i­for­nia com­pa­ny is plan­ning to lay off 114 staffers from its Mor­ris Plains, NJ lo­ca­tion in three waves lat­er this year, ac­cord­ing to a fil­ing with the New Jer­sey De­part­ment of La­bor. The lay­offs are com­ing at the same site of Im­munomedics’ for­mer head­quar­ters, a Gilead spokesper­son told End­points News.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters